Conclusions
The authors conclude that individuals with SARS due to COVID‑19 requiring IMV have high mortality. In addition, an association of mortality with an age of >60 years and the use of azithromycin was observed.
References
  1. Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus Disease-2019 (COVID‑19): mechanism of action, detection and recent therapeutic strategies. Virology . 2020;551: 1-9. doi: 10.1016/j.virol.2020.08.011
  2. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk factors associated with mortality among patients with COVID‑19 in intensive care units in Lombardy, Italy. JAMA Intern Med . 2020;180(10): 1345-1355. doi: 10.1001/jamainternmed.2020.3539
  3. Grieco DL, Menga LS, Cesarano M, Rosà T, Spadaro S, Bitondo MM, et al. Effect of helmet noninvasive ventilation vs high-flow nasal oxygen on days free of respiratory support in patients with COVID‑19 and moderate to severe hypoxemic respiratory failure: the HENIVOT randomized clinical trial. JAMA . 2021;325(17): 1731-1743. doi: 10.1001/jama.2021.4682
  4. Shang Y, Pan C, Yang X, Zhong M, Shang X, Wu Z, et al. Management of critically ill patients with COVID‑19 in ICU: statement from frontline intensive care experts in Wuhan, China. Ann Intensive Care . 2020;10(1): 73. doi: 10.1186/s13613-020-00689-1
  5. Amawi H, Abu Deiab GI, AA. AA, Dua K, Tambuwala MM. COVID‑19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. Ther Deliv . 2020;11(4): 245-268.
  6. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2): facts and myths. J Microbiol Immunol Infect . 2020;53(3): 404-412. doi: 10.1016/j.jmii.2020.02.012
  7. Fauci AS, Longo DL, Hauser SL, et al. Harrison Medicina Interna. Rio de Janeiro: McGraw­Hill, 2019; 20ª Edição, v.2.
  8. Lim ZJ, Subramaniam A, Ponnapa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case fatality rates for patients with COVID‑19 requiring invasive mechanical ventilation. A meta-analysis. Am J Respir Crit Care Med . 2021;203(1): 54-66. doi: 10.1164/rccm.202006-2405OC
  9. Greenland S, Daniel R, Pearce N. Outcome modelling strategies in epidemiology: traditional methods and basic alternatives. Int J Epidemiol . 2016;45(2): 565-575. doi: 10.1093/ije/dyw040
  10. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol . 1996;49(12): 1373-1379. doi: 10.1016/s0895-4356(96)00236-3
  11. Damayanthi HDWT, Prabani KIP, Weerasekara I. Factors associated for mortality of older people with COVID 19: A systematic review and meta-analysis. Gerontol Geriatr Med . 2021;7: 23337214211057392. doi: 10.1177/23337214211057392
  12. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID‑19 meta-analysis as a risk factor for death and ITU admission. Nat Commun . 2020;11(1): 6317. doi: 10.1038/s41467-020-19741-6
  13. Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of oral azithromycin vs placebo on COVID‑19 symptoms in outpatients with SARS-CoV‑2 infection: A randomized clinical trial.JAMA . 2021;326(6): 490-498. doi: 10.1001/jama.2021.11517
  14. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for COVID‑19: living systematic review and network meta-analysis. Br J Clin Pharmacol. 2020;370: m2980.
  15. Theoharides TC, Conti P. Dexamethasone for COVID‑19? Not so fast.J Biol Regul Homeost Agents . 2020;34(3): 1241-1243. doi: 10.23812/20-EDITORIAL_1-5
  16. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID‑19.N Engl J Med . 2021;384(8): 693-704. doi: 10.1056/NEJMoa2021436
  17. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tzanninis IG. et al. Emerging treatment strategies for COVID‑19 infection. Clin Exp Med . 2021;21(2): 167-179. doi: 10.1007/s10238-020-00671-y
  18. Naime A, Bacha H, Tanni S. Uso de esteroides no tratamento da COVID‑19. Projeto diretrizes. Associação Médica Brasileira . 2021.
  19. Guérin C, Reignier J, Richard JC. et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;6;368(23): 2159-2168. doi: 10.1056/NEJMoa1214103
  20. Gattinoni L, Tognoni G, Pesenti A, Taccone P, Mascheroni D, Labarta V. et al. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med . 2001;345(8): 568-573. doi: 10.1056/NEJMoa010043
  21. Funakoshi K, Morita T, Kumanogoh A. Longer prehospitalization and preintubation periods in intubated non-survivors and ECMO patients with COVID‑19: A systematic review and meta-analysis. Front Med (Lausanne ). 2021;8: 727101. doi: 10.3389/fmed.2021.727101
Figure 1. Study conduction flowchart according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.
Table 1. Association between hospital death in patients with severe acute respiratory syndrome owing to COVID-19 and sociodemographic data, chronic diseases, lifestyle, and treatment (n = 397).